United BioPharma

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 31

By Therapeutic Area

top 1

Infectious Disease

1100%

R&D Momentum

12/100

Pipeline Velocity

0/100

Trial Completion Rate

78/100

Pipeline Concentration

100/100

Pipeline Freshness

71/100

Activity

Key Events

Apr 1, 2025TrialTo Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

Oct 4, 2024FDAMestinon — PYRIDOSTIGMINE BROMIDE

Dec 31, 2023TrialStudy for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

Dec 30, 2023TrialEvaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Dec 1, 2023TrialUB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

Dec 1, 2023TrialUB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

Jun 1, 2023TrialA Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621

Oct 5, 2022TrialA Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria

4 more events

Dec 2, 2021TrialA Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

Jan 1, 2021TrialStudy for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

Apr 1, 2020Trialthe Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

Apr 9, 2019TrialEvaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

Mestinon9 patentsJun 18, 2038

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Infectious Disease

HIV-1 Infection

UB-421

Infectious Disease

HIV-1 Infection

UB-421Phase 3

Regulatory

Regulatory Timeline

19825 events

FDAJan 1

Mestinon — MESTINON

Application NDA015193 (NDA)

FDAJan 1

Mestinon — MESTINON

Application NDA009829 (NDA)

FDAJan 1

Mestinon — REGONOL

Application NDA017398 (NDA)

FDAJan 1

Mestinon — MESTINON

Application NDA009830 (NDA)

FDAJan 1

Mestinon — MESTINON

Application NDA011665 (NDA)

19892 events

FDAMay 2

Lariam — MEFLOQUINE HYDROCHLORIDE

Application NDA019578 (NDA)

FDAMay 2

Lariam — LARIAM

Application NDA019591 (NDA)

20031 event

FDAFeb 5

Mestinon — PYRIDOSTIGMINE BROMIDE

Application NDA020414 (NDA)

20241 event

FDAOct 4

Mestinon — PYRIDOSTIGMINE BROMIDE

Application NDA217604 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)